Small molecular inhibitors for the treatment of rheumatoid arthritis: progress so far.

Rheumatoid Arthritis (RA) is an autoimmune disease characterized by persistent inflammation and joint damage. The main aim of RA treatment is to control the disease progress. Despite the success of biologicals like Adalimumab, Atlizumab, infliximab, etc.